Evinacumab-dgnb Injection
Evinacumab-dgnb is used in combination with other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol (‘bad cholesterol’) and other fatty substances in the blood in adults and children 5 years of age or older that have homozygous familial hypercholesterolemia (HoFH; an inherited condition in which cholesterol cannot be removed from the body normally). Evinacumab-dgnb is in a class of medications called angiopoietin-like protein 3 (ANGPTL3) inhibitor monoclonal antibodies. It works by decreasing the production of LDL cholesterol and increasing the breakdown of LDL cholesterol and other fatty substances in the body.
Accumulation of cholesterol and fats along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and, therefore, the oxygen supply to your heart, brain, and other parts of your body. Lowering your blood level of cholesterol and fats may help prevent heart disease, angina (chest pain), strokes, and heart attacks.
🔔 How should this medicine be used?
Evinacumab-dgnb comes as a solution (liquid) to be mixed with liquid and injected slowly into a vein over 60 minutes by a doctor or nurse. It is usually given once every 4 weeks.
Evinacumab-dgnb injection may cause serious reactions during the infusion of the medication. A doctor or nurse will monitor you carefully while you are receiving the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms during the infusion: itching at the infusion site, muscle weakness; fever; nausea; or nasal congestion.
Your doctor may need to slow down your infusion or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with evinacumab-dgnb.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
As of August 2020, the most expensive drug in America is Myalept, a drug used to treat leptin deficiency. A month’s worse of this drug costs $71, 306 per month, according to research from GoodRx. Myalept is known as an “orphan drug” because it’s intended to treat a rare disease.
